US · CORT
Corcept Therapeutics Incorporated
- Sector
- Healthcare · Biotechnology
- Headquarters
- Menlo Park, CA 94025
- Website
- corcept.com
Price · as of 2025-12-31
$51.42
Market cap 3.8B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $106.47 | +107.06% |
| Intrinsic Value(DCF) | $58.59 | +13.94% |
| Graham-Dodd Method(GD) | $11.03 | -78.54% |
| Graham Formula(GF) | $19.55 | -61.98% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $4.00 | ||||
| 2012 | $2.02 | $0.83 | $0.00 | ||
| 2013 | $4.08 | $47.62 | $4,469.36 | $0.00 | $0.00 |
| 2014 | $4.00 | $44.43 | $491,756.30 | $0.00 | $0.00 |
| 2015 | $4.07 | $41.82 | $5,467,716.99 | $0.00 | $0.00 |
| 2016 | $10.87 | $51.37 | $24,064.42 | $0.74 | $4.95 |
| 2017 | $16.54 | $68.29 | $11,945.98 | $7.37 | $113.47 |
| 2018 | $12.09 | $41.24 | $3,354.64 | $5.20 | $38.05 |
| 2019 | $11.56 | $53.40 | $539.52 | $7.36 | $24.03 |
| 2020 | $25.69 | $61.03 | $66.34 | $9.13 | $21.00 |
| 2021 | $24.32 | $64.41 | $3.69 | $8.11 | $11.07 |
| 2022 | $20.70 | $64.62 | $4.44 | $9.45 | $16.62 |
| 2023 | $23.64 | $65.23 | $4.42 | $10.02 | $27.94 |
| 2024 | $55.40 | $92.48 | $161.59 | $13.35 | $62.79 |
| 2025 | $35.97 | $106.47 | $177.66 | $11.03 | $19.55 |
AI valuation
Our deep-learning model estimates Corcept Therapeutics Incorporated's (CORT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $106.47
- Current price
- $51.42
- AI upside
- +107.06%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$58.59
+13.94% upside
Graham-Dodd
$11.03
-78.54% upside
Graham Formula
$19.55
-61.98% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CORT | Corcept Therapeutics Inco… | $51.42 | 3.8B | +107% | +14% | -79% | -62% | 38.06 | 5.77 | 4.91 | 49.30 | — | 5.77 | 98.30% | 5.88% | 13.09% | 14.79% | 15.32% | 11.71% | 0.01 | — | 2.92 | 2.60 | -1.67 | -3333.00% | 1279.00% | -2762.00% | 3.80% | 0.85 | 48.48% | 0.00% | 0.00% | 6.58% | 75.23 | 23.77 | 4.43 | 14.49 |
| ABVX | Abivax S.A. | $121.28 | 7.95B | -67% | -97% | — | — | -2.42 | 10.50 | 39.48 | -2.21 | — | 27.39 | 100.00% | -1602.89% | -1633.08% | -148.98% | 2618.19% | -66.22% | 2.40 | -41.33 | 1.84 | 1.72 | 0.27 | -1837.00% | 13354.00% | 5429.00% | -36.31% | -1.66 | 2341.68% | 0.00% | 0.00% | 0.00% | -2.19 | -2.45 | 35.14 | -3.71 |
| AXSM | Axsome Therapeutics, Inc. | $163.89 | 8.38B | -38% | +8,512% | — | — | -45.19 | 93.74 | 12.96 | -48.76 | — | 231.63 | 92.56% | -26.51% | -28.69% | -252.11% | 574.69% | -29.11% | 2.73 | -25.81 | 1.55 | 1.44 | 0.49 | -3856.00% | 6555.00% | -2741.00% | -1.13% | -0.25 | 318.10% | 0.00% | 0.00% | 0.00% | -48.43 | -87.74 | 12.84 | 6.09 |
| CAI | Caris Life Sciences, Inc. | $20.14 | 5.68B | +132% | +659% | — | — | -507.35 | 59.84 | 42.54 | 2965.27 | — | 61.91 | 66.40% | 5.56% | -66.25% | 7.09% | -3.82% | -9.27% | 0.00 | 0.79 | 7.85 | 7.17 | -70.09 | -2963.00% | 9697.00% | -12637.00% | 0.19% | 0.65 | -5.66% | 0.00% | 0.00% | 3.35% | 748.01 | 504.44 | 41.56 | 36.41 |
| CYTK | Cytokinetics, Incorporate… | $62.22 | 7.61B | -4% | -61% | — | — | -9.39 | -11.18 | 83.75 | -10.03 | -38.60 | -11.18 | 100.00% | -695.44% | -891.60% | 197.47% | 179.99% | -55.55% | -1.95 | — | 4.53 | 4.36 | -0.52 | 2433.00% | 37656.00% | 3377.00% | -7.25% | -2.52 | 157.23% | 0.00% | 0.00% | 3.96% | -12.70 | -14.54 | 88.31 | -2.06 |
| HALO | Halozyme Therapeutics, In… | $69.53 | 8.21B | +26% | +70% | -87% | +68% | 26.42 | 171.48 | 5.99 | 9.10 | — | -5.53 | 78.13% | 58.45% | 22.69% | 153.59% | 93.94% | 13.81% | 0.00 | 45.03 | 4.66 | 3.30 | -0.15 | -2536.00% | 3755.00% | 3762.00% | 7.70% | 3.68 | 109.29% | 0.00% | 0.00% | 22.29% | 10.08 | 12.76 | 5.89 | 3.99 |
| JAZZ | Jazz Pharmaceuticals plc | $190.02 | 11.7B | -5% | -56% | -94% | — | -32.61 | 2.69 | 2.72 | 104.22 | — | -5.99 | 88.21% | 5.26% | -8.35% | -8.47% | 2.26% | -3.01% | 0.25 | 1.15 | 1.86 | 0.99 | -2.87 | -16751.00% | 488.00% | -377.00% | 11.17% | 0.60 | 23.02% | 0.00% | 0.00% | 36.04% | 50.37 | 8.72 | 2.65 | 1.65 |
| MRUS | Merus N.V. | $90.00 | 6.83B | -61% | -76% | — | -87% | -13.74 | 4.57 | 84.83 | -9.34 | -117.77 | 4.58 | 37.15% | -752.96% | -595.93% | -42.88% | -391.57% | -34.71% | 0.02 | — | 6.54 | 6.22 | 1.09 | 1167.00% | -1238.00% | 2826.00% | -6.34% | -2.13 | -279.56% | 0.00% | 0.00% | 3.06% | -9.26 | -12.97 | 69.71 | 11.12 |
| NUVL | Nuvalent, Inc. | $101.95 | 7.41B | — | — | — | — | -17.31 | 5.90 | — | -571.33 | -35.43 | 5.90 | 0.00% | — | — | -36.70% | 481.41% | -33.30% | 0.00 | — | 15.27 | 15.05 | 24.96 | 4885.00% | — | 4871.00% | -3.74% | -3.02 | 319.78% | 0.00% | 0.00% | 1.58% | -14.46 | -21.77 | — | 26.05 |
| RNA | Avidity Biosciences, Inc. | $14.75 | 2.28B | +47% | -35% | — | — | -3.00 | 1.22 | 109.48 | -0.66 | -4.17 | 1.22 | 77.87% | -3977.30% | -3650.39% | -43.98% | -9010.06% | -38.88% | 0.06 | — | 9.20 | 8.75 | 0.42 | 7197.00% | 7211.00% | 11555.00% | -32.33% | -3.33 | -8017.39% | 0.00% | 0.00% | 3.65% | -0.60 | -0.68 | 24.04 | 3.18 |
| RYTM | Rhythm Pharmaceuticals, I… | $92.73 | 6.19B | -37% | +215% | — | — | -31.39 | 44.36 | 32.51 | -33.22 | — | 46.13 | 89.73% | -101.19% | -106.41% | -129.46% | 96.50% | -45.05% | 0.03 | -9.33 | 4.41 | 3.92 | 0.29 | -2834.00% | 4583.00% | 241.00% | -1.89% | -1.09 | 58.61% | 0.09% | -2.70% | 0.09% | -30.13 | -49.60 | 30.48 | 13.65 |
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
- CEO
- Joseph K. Belanoff
- Employees
- 500
- Beta
- 0.26
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($58.59 ÷ $51.42) − 1 = +13.94% (DCF, example).